November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Normal cells outcompete and remove mutant cells in the pancreas with the help of the EphA2 receptor.
72 citations
,
July 2008 in “Dermatologic Therapy” CCCA is a scarring hair loss condition mainly in African descent women, possibly caused by genetics and hairstyling, treated with gentle hair care and medications.
June 2024 in “Journal of the European Academy of Dermatology and Venereology” Allergens might contribute to CCCA, so avoiding them could help manage the condition.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
September 2022 in “JAAD Case Reports” COVID-19 may worsen hair loss in people with a certain type of scarring alopecia, but early treatment can help improve symptoms and hair regrowth.
Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
9 citations
,
August 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
86 citations
,
November 2015 in “Journal of Gastroenterology” The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.
October 2014 in “Cancer Research” A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
January 2024 in “Oxford medical case reports” Standard treatment for congenital erythropoietic porphyria was ineffective over five years.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
July 2024 in “Journal of Investigative Dermatology” Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
53 citations
,
October 2011 in “Psychoneuroendocrinology” Finasteride may help improve certain brain function issues linked to dopamine.
December 2016 in “Springer eBooks” Chrousos Syndrome is caused by mutations that make the body less sensitive to glucocorticoids, leading to various symptoms and requiring high-dose treatment.
3 citations
,
April 2025 in “International Journal of Pharmaceutics” Nanocrystals improve alopecia areata treatment by better targeting hair follicles.
February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
114 citations
,
July 2003 in “PubMed” Lack of KSR1 stops certain skin tumors in mice.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
November 2024 in “Journal of Investigative Dermatology” Blocking the JAK/STAT pathway may help reduce skin sensitivity in Xeroderma pigmentosum.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
37 citations
,
August 2016 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.